lomustine has been researched along with Chromosome Deletion in 9 studies
Chromosome Deletion: Actual loss of portion of a chromosome.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The majority of patients with high-risk lower grade gliomas (LGG) are treated with single-agent temozolomide (TMZ) and radiotherapy despite three randomized trials showing a striking overall survival benefit with adjuvant procarbazine, lomustine, and vincristine (PCV) chemotherapy and radiotherapy." | 9.05 | Radiation and chemotherapy for high-risk lower grade gliomas: Choosing between temozolomide and PCV. ( Atkins, KM; Dietrich, J; Loeffler, JS; McDuff, SGR; Oh, KS; Shih, HA, 2020) |
| "The majority of patients with high-risk lower grade gliomas (LGG) are treated with single-agent temozolomide (TMZ) and radiotherapy despite three randomized trials showing a striking overall survival benefit with adjuvant procarbazine, lomustine, and vincristine (PCV) chemotherapy and radiotherapy." | 5.05 | Radiation and chemotherapy for high-risk lower grade gliomas: Choosing between temozolomide and PCV. ( Atkins, KM; Dietrich, J; Loeffler, JS; McDuff, SGR; Oh, KS; Shih, HA, 2020) |
| " This has changed with the long-term follow-up analysis of the EORTC and RTOG trials on procarbazine, lomustine, and vincristine (PCV) chemotherapy in anaplastic oligodendroglioma." | 3.79 | How to use molecular markers when caring for a patient with brain cancer: 1P/19Q as a predictive and prognostic marker in the neuro-oncology clinic. ( van den Bent, MJ, 2013) |
| "AOA tumors with necrosis are to be considered WHO grade IV tumors (GBM)." | 2.74 | Molecular analysis of anaplastic oligodendroglial tumors in a prospective randomized study: A report from EORTC study 26951. ( Allgeier, A; Brandes, AA; Bromberg, JE; Gorlia, T; Grisold, W; Ibdaih, A; Kouwenhoven, MC; Kros, JM; Lacombe, D; Mirimanoff, R; Mokhtari, K; Sipos, L; Teepen, JL; van den Bent, MJ; van Duinen, SG; Vandenbos, F; Vecht, CJ; Wesseling, P, 2009) |
| "Gliomas are the most frequent primary brain tumors." | 2.50 | [Management of gliomas]. ( Chapet, S; Lévy, S; Mazeron, JJ, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (11.11) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (44.44) | 29.6817 |
| 2010's | 3 (33.33) | 24.3611 |
| 2020's | 1 (11.11) | 2.80 |
| Authors | Studies |
|---|---|
| McDuff, SGR | 1 |
| Dietrich, J | 1 |
| Atkins, KM | 1 |
| Oh, KS | 1 |
| Loeffler, JS | 1 |
| Shih, HA | 1 |
| Wick, W | 1 |
| Winkler, F | 1 |
| van den Bent, MJ | 3 |
| Lévy, S | 1 |
| Chapet, S | 1 |
| Mazeron, JJ | 1 |
| Kouwenhoven, MC | 1 |
| Gorlia, T | 2 |
| Kros, JM | 2 |
| Ibdaih, A | 2 |
| Brandes, AA | 2 |
| Bromberg, JE | 1 |
| Mokhtari, K | 1 |
| van Duinen, SG | 1 |
| Teepen, JL | 1 |
| Wesseling, P | 1 |
| Vandenbos, F | 1 |
| Grisold, W | 1 |
| Sipos, L | 1 |
| Mirimanoff, R | 1 |
| Vecht, CJ | 1 |
| Allgeier, A | 1 |
| Lacombe, D | 2 |
| DeAngelis, LM | 1 |
| Dubbink, HJ | 1 |
| Sanson, M | 1 |
| van der Lee-Haarloo, CR | 1 |
| Hegi, M | 1 |
| Jeuken, JW | 1 |
| Taphoorn, MJ | 1 |
| Frenay, M | 1 |
| Dinjens, WN | 1 |
| Buckner, JC | 1 |
| Gesme, D | 1 |
| O'Fallon, JR | 1 |
| Hammack, JE | 1 |
| Stafford, S | 1 |
| Brown, PD | 1 |
| Hawkins, R | 1 |
| Scheithauer, BW | 1 |
| Erickson, BJ | 1 |
| Levitt, R | 1 |
| Shaw, EG | 1 |
| Jenkins, R | 1 |
| Dutcher, JP | 1 |
| Wiernik, PH | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| PHASE III STUDY OF ADJUVANT PROCARBAZINE, CCNU AND VINCRISTINE CHEMOTHERAPY IN PATIENTS WITH HIGHLY ANAPLASTIC OLIGODENDROGLIOMA[NCT00002840] | Phase 3 | 350 participants (Anticipated) | Interventional | 1996-08-31 | Completed | ||
| PHASE II STUDY OF PREIRRADIATION PCV CHEMOTHERAPY IN PATIENTS WITH SUPRATENTORIAL LOW-GRADE GLIOMAS[NCT00002806] | Phase 2 | 43 participants (Actual) | Interventional | 1996-07-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for lomustine and Chromosome Deletion
| Article | Year |
|---|---|
Radiation and chemotherapy for high-risk lower grade gliomas: Choosing between temozolomide and PCV.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain; Brain Neoplasms; Chemoradiotherapy, Adjuvant; | 2020 |
[Management of gliomas].
Topics: Age Factors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Alkylating; Antineoplastic Co | 2014 |
3 trials available for lomustine and Chromosome Deletion
| Article | Year |
|---|---|
Molecular analysis of anaplastic oligodendroglial tumors in a prospective randomized study: A report from EORTC study 26951.
Topics: Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Cell Proliferation; Ch | 2009 |
MGMT promoter methylation is prognostic but not predictive for outcome to adjuvant PCV chemotherapy in anaplastic oligodendroglial tumors: a report from EORTC Brain Tumor Group Study 26951.
Topics: Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Chemotherapy, Adjuvant | 2009 |
Phase II trial of procarbazine, lomustine, and vincristine as initial therapy for patients with low-grade oligodendroglioma or oligoastrocytoma: efficacy and associations with chromosomal abnormalities.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Chromosome Aber | 2003 |
4 other studies available for lomustine and Chromosome Deletion
| Article | Year |
|---|---|
Regimen of procarbazine, lomustine, and vincristine versus temozolomide for gliomas.
Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neop | 2018 |
How to use molecular markers when caring for a patient with brain cancer: 1P/19Q as a predictive and prognostic marker in the neuro-oncology clinic.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chromosome Deletion; Chromosomes, H | 2013 |
Anaplastic glioma: how to prognosticate outcome and choose a treatment strategy. [corrected].
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; | 2009 |
Acute leukemia in a patient cured of diffuse histiocytic lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Chromosome Deletion; Chromosomes, Human, | 1986 |